Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability: 2013-2024

Historic Non-Current Deferred Tax Liability for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Dec 2024 value amounting to $273,000.

  • Lineage Cell Therapeutics' Non-Current Deferred Tax Liability changed negligibly% to $273,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $273,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $273,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Lineage Cell Therapeutics' Non-Current Deferred Tax Liability amounted to $273,000 in FY2024, which was down 0.00% from $273,000 recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Non-Current Deferred Tax Liability registered a high of $2.1 million during FY2020, and its lowest value of $273,000 during FY2023.
  • Over the past 3 years, Lineage Cell Therapeutics' median Non-Current Deferred Tax Liability value was $273,000 (recorded in 2024), while the average stood at $874,000.
  • Data for Lineage Cell Therapeutics' Non-Current Deferred Tax Liability shows a maximum YoY plummeted of 86.85% (in 2023) over the last 5 years.
  • Lineage Cell Therapeutics' Non-Current Deferred Tax Liability (Yearly) stood at $2.1 million in 2020, then remained steady at $2.1 million in 2021, then remained steady at $2.1 million in 2022, then slumped by 86.85% to $273,000 in 2023, then remained steady at $273,000 in 2024.